Since PARPi have been only recently implemented in clinical trials for patients with IDH-mutant cancers [29], the potential mechanisms of PARPi resistance in this context remain undefined, highlighting the need for further studies to elucidate possible resistance pathways and to potentially guide patient selection, trial design, and new therapeutic strategies. The gene discussed is IDH1; the disease is cancer.